

**84.** A method for identifying a bivalent compound which mediates degradation/disruption of PRMT5, the method comprising:

providing a heterobifunctional test compound comprising a PRMT5 ligand conjugated to a degradation/disruption tag;

contacting the heterobifunctional test compound with a cell comprising a ubiquitin ligase and PRMT5;

determining whether PRMT5 levels decrease in the cell; and

identifying the heterobifunctional test compound as a bivalent compound which mediates degradation/reduction of PRMT5 levels decrease in the cell.

**85.-86.** (canceled)

**87.** A bifunctional compound having the formula corresponding to YS31-58, YS31-60, YS31-61, YS31-62, YS31-63, YS31-64, YS31-67, YS31-68, YS31-69, YS43-6, YS43-7, YS43-8, YS43-16, YS43-19, YS43-20, YS43-21, YS43-22, YS43-25, YS43-28, YS43-29, YS43-30, YS43-31, YS43-32, YS43-33, YS43-34, YS43-37, YS-43-45, YS43-52, YS43-53 or YS43-54.

**88.** A bifunctional compound according to claim **87**, having the formula corresponding to YS31-60, YS31-61, YS31-62, YS31-63, YS31-67, YS31-69, YS43-7, YS43-8, YS43-16, YS43-20, YS43-21, YS43-22, YS43-25, YS43-29, YS43-30, YS43-31, YS43-32, YS43-33, YS43-34, YS43-37 or YS-43-45.

**89.** A bifunctional compound according to claim **88**, having the formula corresponding to YS31-60, YS31-69, YS43-8, YS43-16, YS43-20, YS43-21 or YS43-22.

\* \* \* \* \*